Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Amoxicillin for Oral Suspension USP 125mg/5mL and 250mg/5mL.
Amoxicillin for Oral Suspension USP 125mg/5mL and 250mg/5mL is the generic equivalent to the reference listed drug product (RLD), Amoxicillin for Oral Suspension, 125mg/5 mL and 250mg/5mL respectively of Teva Pharmaceutical Industries and indicated in the treatment of infections due to susceptible βetalactamase-negative strains of the designated microorganisms.
According to IMS, the product has a market size of approximately $19 million for the twelve months ending July 2014. These ANDAs has been approved out of Unit XII, Semi-Synthetic Penicillin (SSP) formulation facility in Hyderabad, India.
Aurobindo now has a total of 195 ANDA approvals (169 Final approvals including 7 from Aurolife Pharma LLC and 26 Tentative approvals) from USFDA.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: